Zymeworks: Good Data, Lots Of Cash, Stagnant Stock

This post was originally published on this site

Pharmaceutical industry and drug manufacturing

Extreme Media

Last October, in an article, I left Zymeworks (NASDAQ:ZYME) with a promise of Biliary Tract Cancer pivotal data of zanidatamab zovodotin by the end of 2022, which I considered a major catalyst for this small-cap company. As

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you.